Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$885.55 USD

885.55
1,972,736

-5.52 (-0.62%)

Updated Oct 3, 2024 04:00 PM ET

After-Market: $885.00 -0.55 (-0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (32 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Nalak Das headshot

Wall Street Regains Momentum on Vaccine Hopes: 5 Top Picks

Investment in momentum stocks with a favorable Zacks Rank may be fruitful in the near term. These include Fulgent Genetics (FLGT), II-VI (IIVI), General Motors (GM), Flagstar Bancorp (FBC) and Lear (LEA).

Merck's (MRK) Keytruda Gets FDA Nod for Severe Breast Cancer

The FDA approves Merck's (MRK) Keytruda combo for the treatment of patients with metastatic triple-negative breast cancer. This marks the first nod for Keytruda in the breast cancer setting.

Kinjel Shah headshot

Pharma Stock Roundup: PFE Coronavirus Data, FDA Emergency Tag for LLY COVID-19 Drug

Eli Lilly (LLY) and Pfizer (PFE) provide updates on their coronavirus vaccine/antibody candidates.

Sanghamitra Saha headshot

3 Reasons to Bet on Healthcare ETFs

The broader medical sector should be in the spotlight now on hopes of a coronavirus vaccine and the likelihood of a divided congress.

Stock Market News for Nov 11, 2020

Wall Street had a mixed day on Tuesday with investor rushing to sell of tech stocks that had had dream run during the virus-induced lockdown, while they put money on sectors that took a beating during the pandemic.

Ritujay Ghosh headshot

Vaccine Hopes Rise as Pharma Giants Inch Closer Toward Success

Stocks of Eli Lilly and Company (LLY), Pfizer, Inc. (PFE) and Moderna, Inc. (MRNA) have been in focus since the coronavirus outbreak as they have been the frontrunners in the vaccine race.

Reopening Stocks Gain on Vaccine Hopes

Reopening Stocks Gain on Vaccine Hopes

Biohaven (BHVN) Q3 Earnings Miss, Nurtec Uptake Promising

Biohaven's (BHVN) recently approved migraine drug, Nurtec ODT, continues to demonstrate strong launch uptake.

Mark Vickery headshot

Blue Chips & Tech Going Separate Directions: PFE, GOOGL, FB, LLY & More

The last time we saw the Dow surge strongly ahead while the Nasdaq dipped into the red was back in 2000, when the tech bubble of the pre-Y2K market began to burst.

Radius' (RDUS) Q3 Loss Matches Estimates, Revenues Miss

Radius (RDUS) reports an in-line loss but misses sales estimates in the third quarter.

Nektar (NKTR) Stock Up 3% on Q3 Earnings and Revenue Beat

Nektar (NKTR) reports encouraging third-quarter 2020 results. Enrollment in clinical studies back on track.

Incyte (INCY) Q3 Earnings & Sales Miss, Jakafi Demand Strong

Incyte (INCY) misses earnings and sales expectations in the third quarter. However, the company's lead drug, Jakafi, reports encouraging growth.

The Zacks Analyst Blog Highlights: Google, Johnson & Johnson, Union Pacific Corp, Eli Lilly, Charter Communications and Anheuser-Busch InBev

The Zacks Analyst Blog Highlights: Google, Johnson & Johnson, Union Pacific Corp, Eli Lilly, Charter Communications and Anheuser-Busch InBev

What Awaits AVEO Pharmaceuticals (AVEO) in Q3 Earnings?

On AVEO Pharmaceuticals' (AVEO) third-quarter earnings call, investor focus will be on the updates related to its NDA that seeks an approval for tivozanib to treat RCC in the United States.

Sheraz Mian headshot

Top Research Reports for Alphabet, Johnson & Johnson & Union Pacific

Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), Johnson & Johnson (JNJ) and Union Pacific (UNP).

The Zacks Analyst Blog Highlights: Eli Lilly, Merck, Pfizer, Novartis, AstraZeneca and J&J

The Zacks Analyst Blog Highlights: Eli Lilly, Merck, Pfizer, Novartis, AstraZeneca and J&J

Kinjel Shah headshot

Pharma Stock Roundup: Q3 Earnings, Resumption of AZN/JNJ Coronavirus Vaccine Study

Eli Lilly (LLY), Merck (MRK), Pfizer (PFE), Novartis (NVS) and others release Q3 results

Novo Nordisk's (NVO) Q3 Earnings Beat Estimates, Sales Miss

Novo Nordisk (NVO) misses earnings and sales estimates in the third quarter of 2020.

Gilead (GILD) Beats on Q3 Earnings & Sales, Lowers '20 View

Gilead (GILD) reports better-than-expected results for the third quarter owing to Veklury sales. However, the company lowers annual guidance.

United Therapeutics (UTHR) Q3 Earnings & Sales Beat Estimates

United Therapeutics' (UTHR) third-quarter earnings and sales beat estimates. Higher sales of Orenitram and Tyvaso offset lower sales of Remodulin and Adcirca.

Company News for Oct 28, 2020

Companies In The News Are: PFE, LLY, MMM, SHW.

Lilly (LLY) Q3 Earnings & Revenues Lag Estimates, Stock Down

Eli Lilly (LLY) misses on both earnings and sales for the third quarter. The company reiterates its revenue guidance for 2020.

Eli Lilly (LLY) Q3 Earnings and Revenues Miss Estimates

Lilly (LLY) delivered earnings and revenue surprises of -12.50% and -2.36%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Roche (RHHBY) Inks Deal to Develop Oral Coronavirus Treatment

Roche (RHHBY) signs a contract with privately-held Atea Pharmaceuticals for jointly developing AT-527, an oral treatment for COVID-19 patients.

Sweta Killa headshot

Healthcare to Post Solid Q3 Earnings Growth: ETFs in Focus

The healthcare is expected to witness substantial earnings growth of 5.1% in the third quarter, representing the second strongest sector this earnings season.